des chapter 9 references - information and library...

DES References

DESIGN AND DEVELOPMENT OF NANO SIZED OCULAR DRUG DELIVERY SYSTEM 232 Jamia Hamdard

Chapter 9

REFERENCES

Abdelbary G. Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-

coated liposomes. Pharm Dev Technol. 2011; 16:44-56.

Abdelkader H, Ismail S, Kamal A, Alany RG. Preparation of niosomes as

an ocular delivery system for naltrexone hydrochloride: physicochemical

characterization. Pharmazie. 2010; 65(11):811-817.

Adibkia K, Omidi Y, Siahi MR, Javadzadeh AR, Barzegar-Jalali M, Barar J, Maleki

N, Mohammadi G, Nokhodchi A. Inhibition of endotoxin-induced uveitis by

methylprednisolone acetate nanosuspension in rabbits. J Ocul Pharmacol Ther.

2007; 23:421–432.

Adibkia K, Siahi Shadbad MR, Nokhodchi A, Javadzedeh A, Barzegar-Jalali M,

Barar J, Mohammadi G, Omidi Y.. Piroxicam nanoparticles for ocular delivery:

physicochemical characterization and implementation in endotoxininduced uveitis.

J Drug Target. 2007; 15:407–416.

Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a

mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm. 2005; 290:

155-159.

Agnihotri SM, Vavia PR Diclofenac-loaded biopolymeric nanosuspensions for

ophthalmic application. Nanomedicine. 2009; 5:90-95.

Akhter S, Talegaonkar S, Khan ZI, Jain GK, Khar RK, Ahmad FJ. Assessment of

ocular pharmacokinetics and safety of Ganciclovir loaded Nanoformulation.

Biomed Nanotechnol. 2011; 7:144-145.

Alany RG, Rades T, Nicoll J, Tucker IG, Davies NM.. W/O microemulsions for

ocular delivery: Evaluation of ocular irritation and precorneal retention. J Control

Release. 2006; 111:145-152.

Alonso MJ. Nanomedecine for overcoming biological barriers. Biomed

Pharmacother. 2004; 58:168-172.

Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug carrier

for transdermal delivery of ketorolac. Eur J Pharm Biopharm. 2005; 59:485–490.

Ansari MJ, Kohli K, and Dixit N. Microemulsions as potential drug delivery

systems: a review. PDA J Pharm Sci Technol. 2008;62:66–79.

DES References


Chapter 9

Artusson P, Lindmark T, Davis SS, and Illum L. Effect of chitosan on the

permeability of monolayers of intestinal epithelial cells (caco-2). Pharm Res. 1994;

11:1358-1361.

Asberg A, Hansen CN and Reubsaet. L. Determination of ganciclovir in different

matrices from solid organ transplanted patients treated with a wide range of

concomitant drugs. J Pharm Biomed Anal. 2007; 43:1039-1044.

Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye:

in vitro evaluation of novel solid lipid nanoparticleformulation using human cornea

construct. Int J Pharm. 2008; 355:307-313.

Attama AA, Reichl S, Müller-Goymann CC. Sustained release and permeation of

timolol from surface-modified solid lipid nanoparticles through bioengineered

human cornea. Curr Eye Res. 2009; 34:698-705.

Attwood D. Microemulsions. In J. Kreuter (Ed.), Colloidal drug delivery Systems.

Marcel Dekker; New York: pp. 31-71, 1994

Badawi AA, El-Laithy HM, El Qidra RK, El Mofty H, El Dally M. Chitosan based

nanocarriers for indomethacin ocular delivery. Arch Pharm Res. 2008; 31:1040–

1049.

Bagwe RP, Kanicky JR, Palla BJ, Patanjali PK, Shah DO. Improved drug delivery

using microemulsions: rationale, recent progress, and new horizons. Crit Rev Ther

Drug Carrier Syst. 2001; 18:77-140.

Barbault-Foucher S, Gref R, Russo P, Guechot J, Bochot A.. Design of poly–

caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular

delivery. J Control Release 2002; 83:365-375.

Basaran E, Demirel M, Sirmagül B, Yazan Y. Cyclosporine-A incorporated

cationic solid lipid nanoparticles for ocular delivery. J Microencapsul. 2010; 27:37-

47.

Benita S, Levy MY. Submicron emulsions as colloidal drug carriers for intravenous

administration: comprehensive physicochemical characterization. J Pharm Sci.

1993; 82: 1069-1079.

Bochot A, Fattal E, Boutet V, Deverre JR, Jeanny JC, Chacun H, Couvreur P.

Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest

Ophthalmol Vis Sci. 2002; 43:253–259.

DES References


Chapter 9

Bochot A, Mashhour B, Puisieux F, Couvreur P, Fattal E. Comparison of the ocular

distribution of a model oligonucleotide after topical instillation in rabbits of

conventional and new dosage forms. J Drug Target. 1998; 6:309–313.

Boulieu R, Bleyzac N, Ferry S. High-performance liquid chromatographic

determination of ganciclovir in plasma. J chromat. 1991; 567 :481-484.

Boulieu R, Bleyzac N, Ferry S. Modified high-performance liquid chromatographic

method for the determination of ganciclovir in plasma from patients with severe

renal impairment. J chromat. 1991; 571: 331-333.

Bourlais CL, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug

delivery systems-recent advances. Prog Retin Eye Res. 1998; 17:33-58.

Budai L, Hajdu M, Budai M, Gróf P, Béni S, Noszál B, Klebovich I, Antal I.. Gels

and liposomes in optimized ocular drug delivery: studies on ciprofloxacin

formulations. Int J Pharm. 2007; 343:34-40

Buech G, Bertelmann E, Pleyer U, Siebenbrodt I, and Borchert HH. Formulation of

sirolimus eye drops and corneal permeation studies. J Ocul Pharmacol Ther. 2007;

23:292–303.

Cable C. An examination of the effects of surface modifications on the

physicochemical and biological properties of non-ionic surfactant vesicles. PhD

Thesis 1989; University of Strathclyde, Glasgow, UK

Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. Improved ocular bioavailability of

indomethacin by novel ocular drug carriers. J Pharm Pharmacol. 1996; 48:1147–

1152.

Calvo P, Remunan-Lopez C, Vila-Jato CL, Alonso MJ. Novel hydrophilic chitosan-

polyethylene oxide nanoparticles as protein carriers. J App Poly Sci. 1997; 63: 125-

132.

Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/

ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for

proteins and vaccines. Pharm Res. 1997; 14:1431-1436.

Calvo P, Sanchez A, Martinez J, Lopez MI, Calonge M, Pastor JC, Alonso MJ..

Polyester Nanocapsules as new topical ocular delivery systems for cyclosporin A.

Pharm Res. 1996; 13:311-315.

Calvo P, Vila-Jato JL, Alonso MJ.. Comparative in vitro evaluation of several

colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug

carriers. J Pharm Sci. 1996; 85:530–536.

DES References


Chapter 9

Calvo P, Vila-JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules

as ocular drug carriers. Int J Pharm 1997; 153:41-50.

Campanero MA, Sadaba B, García-Quetglas E, Azanza JR. Development and

validation of a sensitive method for the determination of ganciclovir in human

plasma samples by reversed-phase high-performance liquid chromatography. J

Chromat B: Biomed Sci App. 1998; 706:311-317.

Cantarovich M, Besner J-G, Barkun JS, Elstein E, Loertscher R. Two-hour

cyclosporine level determination is the appropriate tool to monitor Neoral therapy.

Clin Transplantation 1999;12:243-229.

Cavalli R, Gasco R, Chetoni P, Burgalassi S, Saettone MF. Solid lipid

nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;

238:241–245

Chan J, Maghraby GM, Craig JP, Alany RG. Phase transition water-in-oil

microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int

J Pharm. 2007; 328:65-71.

Chen H, Chang X, Du D, Li J, Xu H, Yang X. Microemulsion-based hydrogel

formulation of ibuprofen for topical delivery. Int J Pharm. 2006 ; 315 :52–58.

Chen R, Qian Y, Li R, Zhang Q, Liu D, Wang M, Xu Q.. Methazolamide Calcium

Phosphate Nanoparticles in an Ocular Drug Delivery System. Yakugaku Zasshi.

2010; 130:419-424.

Chetoni P, Rossi S, Burgalassi S, Monti D, Mariotti S, Saettone MF. Comparison of

Liposome-Encapsulated Acyclovir with Acyclovir Ointment: Ocular

Pharmacokinetics in Rabbits. J Ocul Pharmacol Ther. 2004; 20:169-177.

Chrai SS, Robinson JR. Ocular evaluation of methylcellulose vehicle in albino

rabbits. J Pharm Sci. 1974; 63:1218-1223.

Clayton PT, Doig M, Soudabeh G, Meaney C, Taylor C, Leonard JV, et al.

Screening for medium chain acyl-CoA dehydrogenase deficiency using electrospray

ionisation tandem mass spectrometry. Arch Dis Child 1998; 79:109-115.

Colin J, Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular

herpes. Clin. Ophthalmo. 2007; 1: 441.

Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular

herpes. Clin Ophthal. 2007; 1:441-453.

DES References


Chapter 9

Conti B, Bucolo C, Giannavola C, Puglisi G, Giunchedi P, Conte U. Biodegradable

microspheres for the intravitreal administration of acyclovir: in vitro in vivo

evaluation. Eur J Pharm Sci. 1997; 5:287-293.

Cortesi R, Argnani R, Esposito E, Dalpiaz A, Scatturin A, Bortolotti F, Lufino M,

Guerrini R, Cavicchioni G, Incorvaia C, Menegatti E, Manservigi R. Cationic

liposomes as potential carriers for ocular administration of peptides with anti-

herpetic activity. Int J Pharm. 2006; 317:90–100.

Daniels AB, Kohanim S, Huynh N, Durand ML, Young LH. Antiviral

chemoprophylaxis for ocular viral infections in hematopoietic stem cell and bone

marrow transplant patients. Int Ophthalmol Clin. 2011; 51:53-66.

Dao Y, Jiao Z, Zhong M. Simultaneous determination of aciclovir, ganciclovir, and

penciclovir in human plasma by high-performance liquid chromatography with

fluorescence detection. J Chromat B. 2008; 867:270-276.

Das S, Suresh PK, Desmukh R. Design of Eudragit RL 100 nanoparticles by

nanoprecipitation method for ocular drug delivery. Nanomedicine. 2010; 6:318-323.

Das, S Banerjee R, Bellare J. Aspirin Loaded Albumin Nanoparticles by

Coacervation: Implications in Drug Delivery. Trends Biomater. Artif. Organs.

2005; 18:203-212

Davies NM, Farr SJ, Hadgraft J, Kellaway IW. Evaluation of mucoadhesive

polymers in ocular drug delivery: I. Viscous solution. Pharm. Res. 1991; 8:1039-

1043.

Davies NM, Wang G, Tucker IG. Evaluation of a hydrocortisone/hydroxypropyl-β-

cyclodextrin solution for ocular drug delivery. Int. J. Pharm. 1997; 156:201-209.

Davies NM. Biopharmaceutical Considerations in Topical Ocular Drug Delivery.

Clin Exp Pharmacol Physiol. 2000; 27:558-562.

Davis JL, Gilger BC, Robinson MR. Novel approaches to ocular drug delivery.

Curr Opin Mol Ther. 2004; 6:195-205.

De Campos AM, Diebold Y, Carvaiho ELS, Sanchez A, and Alonso MJ. Chitosan

nanoparticles as new ocular drug delivery system: in vitro stability, in vivo fate, and

cellular toxicity. Pharm Res. 2004; 21: 803-810.

De Campos AM, Sanchez A, Alonso MJ. Alonso. Chitosan nanoparticles: a new

vehicle for the improvement of the delivery of drugs to the ocular surface.

Application to cyclosporine A Int J Pharm. 2001; 224:159-168.

DES References


Chapter 9

De Campos AM, Sanchez A, Gref R, Calvo P, Alonso MJ. The effect of a PEG

versus a chitosan coating on the interaction of drug colloidal carriers with the ocular

mucosa, Eur J Pharm Sci. 2003; 20:73–81.

de Kozak Y, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, Naud

MC, Garcia E, Couvreur P. Intraocular injection of tamoxifen-loaded nanoparticles:

a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol. 2004;

34:3702-3712.

de la Fuente M, Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles as protein

and gene carriers to mucosal surfaces. Nanomedicine . 2008; 3:845–857.

de la Fuente M, Seijo B, Alonso MJ. Bioadhesive hyaluronan–chitosan

nanoparticles can transport genes across the ocular mucosa and transfect ocular

tissue, Gene Ther. 2008; 15:668–676.

de la Fuente M, Seijo B, Alonso MJ. Design of novel polysaccharidic

nanostructures for gene delivery. Nanotech. 2008; 19:1–9.

Deng Y, Xu J, Li X. Preparation and lacrimal pharmacokinetics of eye drops of

puerarin liposomes in rabbit tears. Zhongguo Zhong Yao Za Zhi. 2010; 35:301-304.

Devaraj GN, Parakh SR, Devraj R, Apte SS, Rao BR, Rambhau D. Release studies

on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol. J

Colloid Interface Sci. 2002; 251:360–365.

Diepold R, Kreuter J, Himber J, Gurny R, Lee VH, Robinson JR, Saettone MF,

Schnaudigel OE. Comparison of different models for the testing of pilocarpine

eyedrops using conventional eyedrops as a novel depot formulation (nanoparticles).

Graefe’s Arch. Clin Exp Ophthalmol 1989; 227:188-193.

Dillen K, Vandervoort J, Van den Mooter G, Ludwig A. Evaluation of

ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int J Pharm.

2006; 314:72-82.

Dodane V, Khan MA, and Merwin JR. Effect of chitosan on epithelium

permeability and structure. Int J Pharm. 1999; 182:21-32.

Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and

clinical uses. Surv Ophthalmol. 2009;54: 321-38.

Dornish M, Hagan A, Hansson E, Pecheur C, Verdier F, and Skaugrud Q. Safety

of protasan: ultrapure chitosan salts for biomedical and pharmaceutical use. Seventh

International Conference on Chitin and Chitosan. 1997.

DES References


Chapter 9

du Toit LC, Pillay V, Choonara YE, Govender T, Carmichael T. Ocular drug

delivery - a look towards nanobioadhesives. Expert Opin Drug Deliv. 2011; 8:71-

94.

Duanand X, Sheardown H. Dendrimer crosslinked collagen as a corneal tissue

engineering scaffold: mechanical properties and corneal epithelial cell interactions.

Biomaterials. 2006; 27:4608–4617.

Duchene D, Touchard F, Peppas NA. Pharmaceutical and medical aspects of

bioadhesive systems for drug administration. Drug Dev Ind. Pharm. 1998; 14:283-

318.

Duchfine D, Touchard F, Peppas NA. Pharmaceutical and medical aspects of

bioadhesive systems of drug administration. Drug Dev Ind Pharm 1988; 14:283-

318.

Durrani AM, Davies NM, Thomas M, Kellaway IW. Pilocarpine bioavailability

from a mucoadhesive liposomal ophthalmic drug delivery system. Int. J. Pharm.

1992; 88:409-415.

Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS. Systemic

therapy with conventional and novel immunomodulatory agents for ocular

inflammatory disease. Surv Ophthalmol. 2011; 56: 474-510.

El-Gazayerly ON, Hikal AH. Preparation and evaluation of acetazolamide

liposomes as ocular delivery systems. Int J Pharm. 1997; 158:121–127.

Enriquez de Salamanca A, Diebold Y, Calonge M, Garcia-Vazquez C, Callejo S,

Vila A, Alonso MJ. Chitosan nanoparticles as a potential drug delivery system for

the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest

Ophthalmol. Vis Sci. 2006; 47:1416–1425.

Fattal E, Bochot A. Ocular delivery of nucleic acids: antisense oligonucleotides,

aptamers and siRNA. Adv Drug Del Rev 2006; 58:1203-1223.

Felt O, Furrer P, Mayer JM, Plazonnet B, Buri P, Gurny R. Topical use of chitosan

in ophthalmology: tolerance assessment and evaluation of pre-corneal retention. Int

J Pharm 1999; 180:185-193.

Fitzgerald P, Hadgraft J, Kreuter J, Wilson CG. A γ-scintigraphic evaluation of

microparticulate ophthalmic delivery systems: liposomes and nanoparticles. Int J

Pharm. 1987; 40:81-84.

Friess W. Collagen-material for drug delivery. Eur J Pharm Biopharm 1998;

45:113-136.

DES References


Chapter 9

Furrer P, Plazonnet B, Mayer JM, Gurny R. Application of in vivo confocal

microscopy to the objective evaluation of ocular irritation induced by surfactants.

Int J Pharm. 2000; 207:89-98.

Gan L, Gan Y, Zhu C, Zhang X, Zhu J. Novel microemulsion in situ electrolyte-

triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in

vitro and in vivo results. Int J Pharm. 2009; 365:143-149.

Genta I, Conti B, Perugini P, Pavaneto F, Spadaro A, Puglisi G. Bioadhesive

microspheres for ophthalmic administration of acyclovir. J Pharm Pharmacol. 1997;

49:737–742.

Giannavola C, Bucolo C, Maltese A, Paolino D, Vandelli MA, Puglisi G, Lee VH,

Fresta M. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic

acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm

Res. 2003; 20:584-590.

Gokçe EH, Sandri G, Egrilmez S, Bonferoni MC, Guneri T, Caramella C.

Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug

release in rabbit eyes. Curr Eye Res. 2009; 34:996-1003.

Greaves JL, Olejnik O, Wilson CG. Polymers and the precorneal tear film. S.T.P.

Pharma Sciences. 1992; 2:13-33.

Greaves JL, Wilson CG, Birmingham AT. Assessment of the precorneal residence

of an ophthalmic ointment in healthy subjects. Br J Clin Pharmacol. 1993; 35:188-

192.

Gregoriadis G, Florence AT. Liposomes in drug delivery: Clinical, diagnostic and

ophthalmic potential Drugs. 1993; 45:15–28.

Grevel J, Welsh MS, Kahan BD. Cyclosporine monitoring in renal transplantation:

area under the curve monitoring is superior to trough-level monitoring. Ther Drug

Monit 1989; 11:246-248.

Guinedi AS, Mortada ND, Mansour S, Hathout RM. Preparation and evaluation of

reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of

acetazolamide. Int J Pharm. 2005; 306:71–82.

Guo LSS, Sarris AM, Levy MD. A safe bioadhesive liposomal formulation for

ophthalmic applications. Invest Ophthalmol Vis Sci 1989; 29:439.

Gupta C, Daechsel AK, Chauhan A. Source Interaction of ionic surfactants with

cornea-mimicking anionic liposomes. Langmuir. 2011; 27:10840-10846

DES References


Chapter 9

Gupta H, Aqil M, Khar RK, Ali A, Bhatnagar A, Mittal G. Sparfloxacin-loaded

PLGA nanoparticles for sustained ocular drug delivery. Nanomedicine. 2010;

6:324-333.

Gurny R. Latex systems. In: Breimer DD, Speiser P. editors. Topics in

Pharmaceutical Sciences. Elsevier Science Publishers, Amsterdam, 1983. p. 277–

288.

Gurny R. Ocular therapy with nanoparticles. In: Guiot P, Couvreur P. editors.

Polymeric Nanoparticles and Microspheres. CRC Press, Boca Raton; 1986. p. 127–

136.

Hanrahan F, Campbell M, Nguyen AT, Suzuki M, Kiang AS, Tam LC, Gobbo OL,

Dhubhghaill SN, Humphries MM Kenna PF. On Further Development of Barrier

Modulation as a Technique for Systemic Ocular Drug Delivery. Adv Exp Med Bio.

2012; 723:155-159.

Hao J, Fang X, Zhou Y, Wang J, Guo F, Li F, Peng X. Development and

optimization of solid lipid nanoparticle formulation for ophthalmic delivery of

chloramphenicol using a Box-Behnken design. Int J Nanomedicine. 2011; 6:683-

692.

Hao Y, Zhao F, Li N, Yang Y, Li K. Studies on a high encapsulation of colchicine

by a niosome system. Int J Pharm. 2002; 244:73–80.

Harmia T, Kreuter J, Speiser P, Boye T, Gurny R, Kubi A. Enhancement of the

myotic response of rabbits with pilocarpine-loaded polybutylcyanoacrylate

nanoparticles. Int J Pharm. 1986; 33:187-193.

Hasse A, Keipert S. Development and characterization of microemulsions for

ocular application. Eur J Pharm Biopharm. 1997; 43:179–183.

Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular

delivery system for acetazolamide: in vitro and in vivo studies. AAPS Pharm

SciTech. 2007; 8:1.

Hirano S, Seino H, Akiyama I, Nonaka I. Chitosan: a biocompatible material for

oral and intravenous administration. In: Gebelein CG, Dunn RL, editors, Progress

in biomedical polymers. Plenum Press, New York; 1990. p. 283-289.

Hosny KM. Ciprofloxacin as Ocular Liposomal Hydrogel. AAPS PharmSciTech.

2010; 11:241-246.

Hosny KM. Optimization of gatifloxacin liposomal hydrogel for enhanced

transcorneal permeation. J Liposome Res. 2010; 20:31-37

DES References


Chapter 9

Hosny KM. Preparation and evaluation of thermosensitive liposomal hydrogel for

enhanced transcorneal permeation of ofloxacin. AAPS PharmSciTech. 2009;

10:1336-1342.

Ibrahim HK, El-Leithy IS, Makky AA. Mucoadhesive nanoparticles as carrier

systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol

Pharm. 2010; 7:576-585.

Ihre HR, Padilla OL, Jesus D, Szoka Jr. FC, Frechet JM. Polyester dendritic

systems for drug delivery applications: design, synthesis, and characterization.

Bioconjug Chem 2002; 13:443–452.

Illum L. Chitosan and its uses as a pharmaceutical excipient. Pharm Res. 1998;

15:1326-1331.

Jain GK, Jain N, Pathan SA, Akhter S, Talegaonkar S, Chander P, Khar RK,

Ahmad FJ. Ultra high-pressure liquid chromatographic assay of moxifloxacin in

rabbit aqueous humor after topical instillation of moxifloxacin nanoparticles.

Journal of Pharmaceutical and Biomed Anal. 2010; 52:110-113.

Jarvinen K, Jarvinen T, Urtti A. Ocular absorption following topical delivery. Adv

Drug Deliv Rev. 1995; 16: 3-19.

Jimenez N, Galan J, Vallet A, Egea MA, Garcia ML. Methyl trypsin loaded

poly(D,L-lactide-coglycolide) nanoparticles for contact lens care. J Pharm Sci.

2010; 99:1414-1426.

Joossand K, Chirmule N. Immunity to adenovirus and adeno-associated viral

vectors: implications for gene therapy. Gene Therapy 2003; 10:955–963.

Kalam MA, Sultana Y, Ali A, Aqil M, Mishra AK, Chuttani K. Preparation,

characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as

colloidal ocular drug delivery system. J Drug Target. 2010; 18:191-204.

Kapoor Y, Chauhan A. Ophthalmic delivery of Cyclosporine A from Brij-97

microemulsion and surfactant-laden p-HEMA hydrogels. Int J Pharm. 2008;

361:222-229.

Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM.

Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs.

Int J Pharm. 2007; 340:126-133.

Kaur IP, Aggarwal D, Singh H, Kakkar S. Improved ocular absorption kinetics of

timolol maleate loaded into a bioadhesive niosomal delivery system. Graefes Arch

Clin Exp Ophthalmol. 2010; 248:1467-1472.

DES References


Chapter 9

Kaur IP, Garg A, Singla AK, and Aggarwal D. Vesicular systems in ocular drug

delivery: an overview. Int J Pharm. 2004; 269:1–14.

Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind

Pharm. 2002; 28:473-493.

Kaur IP, Singh M, Kanwar M. Formulation and evaluation of ophthalmic

preparation of acetazolamide. Int J Pharm. 2000; 199:119–127.

Kaur IP, Smitha R. Penetration enhancers and ocular bioadhesives: two new

avenues for ophthalmic drug delivery. Drug Dev Ind Pharm. 2002; 28:353– 369.

Kawakami, K.; Yoshikawa, T.; Moroto, Y.; Kanaoka, E.; Takahashi, K.; Nishihara,

Y.; Masuda, K. Microemulsion formulation for enhanced absorption of poorly

soluble drugs I. Prescription design. J. Control Release, 2002, 81, 65.

Kayser O, Lemke A, Hernandez-Trejo N. The impact of nanobiotechnology on the

development of new drug delivery systems. Curr Pharm Biotechnol. 2005; 6:3-5.

Koch MA, Dodane V, Khan MA, and Merwin JR. Chitosan induced effects on

epithelial morphology as seen by confocal

Krauland AH, Leitner VM, Bernkop-Schnürch A. Improvement in the in situ

gelling properties of deacetylated gellan gum by the immobilization of thiol groups.

J Pharm Sci. 2003; 92:1234-1241.

Kreuter J. Nanoparticles-Preparation and applications. In: Donbrow M. editors.

Microcapsules and Nanocapsules in Medicine and Pharmacy. CRC Press Inc, Boca

Raton; 1992. p. 126–143.

Kupferman A, Pratt MV, Suckewer K, Leibowitz HM. Topically applied steroids in

corneal disease, the role of drug derivative in stromal absorption of dexamethasone.

Arch. Ophthalmol. 1974; 91:373-376.

Lajavardi L, Bochot A, Camelo S, Goldenberg B, Naud MC, Behar-Cohen F, Fattal

E, de Kozak Y. Downregulation of endotoxin-induced uveitis by intravitreal

injection of vasoactive intestinal peptide encapsulated in liposomes. Invest

Ophthalmol Vis Sci 2007; 48:3230–3238.

Lallemand FO, Felt-Baeyens, K, Besseghir F, Behar-Cohen, Gurny R.

Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm.

Biopharm. 2003; 56 :307–318.

Lang JC. Ocular drug delivery conventional ocular formulations. Adv. Drug Deliv.

Rev.1995; 16: 39-43.

DES References


Chapter 9

Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery

systems. Adv Drug Deliv Rev. 2000; 45:89-103.

Le Bourlias CA, Treupel-Acar L, Rhodes CT, Sado PA, Leverge R. New

ophthalmic drug delivery systems. Drug Dev Ind Pharm. 1995; 21:19–59.

Leaker B, Cairns HS. Clinical aspects of cyclosporin nephrotoxicity. Br J Hosp

Med 1994;52:529-534.

Lee VH, Urrea PT, Smith RE, Schanzlin DJ. Ocular drug bioavailability from

topically applied liposomes. Surv. Ophthalmol. 1985; 29:335-348.

Lee VHK, Wood RW, Kreuter J, Harima T, Robinson JR. Ocular drug delivery of

progesterone using nanoparticles. J Microencapsul 1986; 3: 213-218.

Lemarchand C, Gref R, Couvreur P. Polysaccharide-decorated nanoparticles. Eur J

Pharm Biopharm 2004; 58:327-341.

Li CC, Abrahamson M, Kapoor Y, Chauhan A. Timolol transport from

microemulsions trapped in HEMA gels. J Colloid Interface Sci 2007; 315:297–306.

Li N, Zhuang CY, Wang M, Sui CG, Pan WS. Low molecular weight chitosan-

coated liposomes for ocular drug delivery: In vitro and in vivo studies. Drug Deliv.

2012; 19:28-35.

Li R, Jiang S, Liu D, Bi X, Wang F, Zhang Q, Xu Q. A potential new therapeutic

system for glaucoma: solid lipid nanoparticles containing methazolamide J

Microencapsul. 2011; 28:134-141.

Li X, Nie SF, Kong J, Li N, Ju CY, Pan WS. A controlled-release ocular delivery

system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;

363:177-82.

Liu Z, Li J, Nie S, Guo H, Pan W. Effects of Transcutol P on the corneal

permeability of drugs and evaluation of its ocular irritation of rabbit eyes. J Pharm

Pharmacol. 2006; 58:45-50.

Liu Z, Zhang X, Wu H, Li J, Shu L, Liu R, Li L, Li N. Preparation and evaluation

of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and

in vivo.. Drug Dev Ind Pharm. 2011; 37:475-481.

LoBrutto R, Makarov A, Jerkovich A, McGill R, Kazakevich Y, Vivilecchia R.

Enhancing Productivity in the Analytical Laboratory Through the use of Ultra Fast

HPLC in Preformulation/Formulation Development. J Liq Chromat Rel Techn.

2008; 31:2253–2285.

DES References


Chapter 9

Losa C, Marchal-Heussler L, Orallo F, Vila Jato JL, Alonso MJ. Design of new

formulations for topical ocular administration: polymeric nanocapsules containing

metipranolol. Pharm Res 1993; 10:80-87.

Ludwig A, van Haeringen NJ, Bodelier VM, Van Ooteghem M. Relationship

between precorneal retention of viscous eye drops and tear fluid composition. Int.

Ophthalmol. 1992; 16:23-26.

Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv drug

Deliv Rev. 2005; 57:1595-1639.

Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with

Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J

Pharm. 2011; 403:185-191.

Lv FF, Zheng LQ, Tung CH. Phase behavior of the microemulsions and the

stability of the chloramphenicol in the microemulsion-based ocular drug delivery

system. Int J Pharm. 2005;301:237-246.

MacKeen DL. Aqueous formulations and ointments. Int Ophthalmol Clin. 1980; 20:

79-92.

Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by

simplified sparse sampling area under the concentration-time curve. Transplantation

1999; 68:55-62.

Mahalati K, Lawen J, Kiberd B, Belitsky P. Is 3-hour cyclosporine blood level

superior to trough level in early post-renal transplantation period? J Urol 2000;

163:37-41.

Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel:

effect of formulation variables on size distribution. Int J Pharm. 2005; 290:137-144

Mainardes RM, Silva LP. Drug delivery systems: past, present, and future. Cur.

Drug Targets. 2004; 5:449-455.

Mainardes RM, Urban MC, Cinto PO, Khalil NM, Chaud MV, Evangelista RC,

Gremiao MP. Colloidal Carriers for Ophthalmic Drug Delivery. Curr Drug Targets

2005; 6:363-371.

Manconi M, Sinico C, Valenti D, Loy G, Fadda AM. Niosomesas carriers for

tretinoin. I. Preparation and properties. Int J Pharm. 2002; 234:237–248.

Mandal B, Halder KK, Dey SK, Bhoumik M, Debnath MC, Ghosh LK.

Development and physical characterization of chloramphenicol loaded

biodegradable nanoparticles for prolonged release. Pharmazie. 2009; 64:445-449.

DES References


Chapter 9

Manosroi A, Wongtrakul P, Manosroi J, Saki H, Sugawara F, Yuasa M, Abe M.

Characterization of vesicles prepared with various non-ionic surfactants mixed with

Cholesterol. Colloid Surf B: Biointerf. 2003; 30:129–138.

Marano RJ, Toth I, Wimmer N, Brankov M, and Rakoczy PE. Dendrimer delivery

of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of

laser-induced CNV, distribution, uptake and toxicity. Gene therapy. 2005; 12:

1544– 1550.

Marchal-Haussler L, Fessi H, Devissaguet JP, Hoffman M, Maincent P. Colloidal

drug delivery systems for the eye. A comparison of the efficacy of three different

polymers: polyisobutylcyanoacrylate, polylactic-coglycolic acid, poly-epsilon-

caprolactone. Pharm. Sci.1992; 2:98.

Marchal-Heussler L, Sirbat D, Hoffman M, Maincent P. Poly(epsilon-caprolactone)

nanocapsules in carteolol ophthalmic delivery. Pharm Res. 1993; 10:386-390.

McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of

cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;

61:1153-1183.

McGavin, JK, Goa KL. Ganciclovir: an update of its use in the prevention of

cytomegalovirus infection and disease in transplant recipients. Drugs. 2001;

61:1153.

McMullin CM, Kirk B, Sunderland J, White LO, Reeves DS, MacGowan AP. A

simple high performance liquid chromatography (HPLC) assay for aciclovir and

ganciclovir in serum. J Antimicro Chemother. 1996; 38:739-752.

Mehanna MM, Elmaradny HA, Samaha MW. Ciprofloxacin Liposomes as

Vesicular Reservoirs for Ocular Delivery: Formulation, Optimization, and In Vitro

Characterization. Drug Dev and Ind Pharm .2009; 35:583-593

Mehanna MM, Elmaradny HA, Samaha MW. Mucoadhesive liposomes as ocular

delivery system: physical, microbiological, and in vivo assessment. Drug Dev Ind

Pharm. 2010; 36:108-118

Merodio M, Arnedo A, Renedo MJ, Irache JM. Ganciclovir-loaded albumin

nanoparticles: characterization and in vitro release properties. Eur J Pharm Sci

2001; 12:251–259.

Merodio M, Campanero MA, Mirshahi T, Mirshahi M, Irache JM. Development of

a sensitive method for the determination of ganciclovir by reversed-phase high-

performance liquid chromatography. J Chromat A 2000; 870:159-167.

DES References


Chapter 9

Merodio M, Irache JM, Valamanesh F, Mirshahi M. Ocular disposition and

tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in

rats. Biomaterials. 2002; 2397:1587–1594.

Mishra GP, Bagui M, Tamboli V, Mitra AK. Recent applications of liposomes in

ophthalmic drug delivery. J Drug Deliv. 2011; vol1-14

Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. Chitosan–

sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery:

formulation, optimisation and in vitro characterization, Eur. J. Pharm. Biopharm

2008; 68:513–525.

Mucha M, Rheological characteristics of semi- diluted chitosan solutions.

Macromol Chem Physical. 1997; 198:471-484.

Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs--a

review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2004;

113:151-170.

Nagarsenker MS, Londhe VY, and Nadkarni GD. Preparation and evaluation of

liposomal formulations of tropicamide for ocular delivery. Int J Pharm

1999;190:63–71.

Nagarwal RC, Singh PN, Kant S, Maiti P, Pandit JK. Chitosan coated PLA

nanoparticles for ophthalmic delivery: characterization, in-vitro and in-vivo study in

rabbit eye. J Biomed Nanotechnol. 2010; 6:648-657.

Namdeo A, Jain NK. Niosomal delivery of 5-fluorouracil. J Microencapsul. 1999;

16:731–740.

Oellerich M, Armstrong VW, Khan B, Shaw L, Holt DW, Yatscoff R, et al. Lake

Louise Consensus Conference on Cyclosporin Monitoring in Organ

Transplantation: report of the consensus panel. Ther Drug Monit 1995;17:642-654.

Ogata N, Otsuji T, Matsushima M, Kimoto T, Yamanaka R, Takahashi K, Wada M,

Uyama M, Kaneda Y. Phosphorothioate oligonucleotides induction into

experimental choroidal neovascularization by HVJ-liposome system. Curr Eye Res

1999; 18:261–269.

Olejnik, O., 1993. Conventional Systems in Ophthalmic Drug Delivery. In A. K.

Mitra (Ed.), Ophthalmic Drug Delivery Systems, New York, Marcel Dekker, pp.

177-198

DES References


Chapter 9

Ooya T, Lee J, Park K.. Effects of ethylene glycol-based graft, star-shaped, and

dendritic polymers on solubilization and controlled release of paclitaxel. J Control

Release 2003; 93:121–127.

Page T, Sherwood C, Connor JD, Tarnowski T. Simple reversed-phase high-

performance liquid chromatography quantitation of ganciclovir in human serum and

urine. J Chromat B 1996; 675:342-346.

Park H, Robinson JR. Mechanisms of mucoadhesion of poly(acrylic acid)

hydrogels. Pharm Res. 1987; 4:457-464.

Parveen S, Mitra M, Krishnakumar S, Sahoo SK. Enhanced antiproliferative

activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma

cell line. Acta Biomater. 2010; 6:3120-3131

Patton TF, Robinson JR. Ocular evaluation of polyvinyl alcohol vehicle in rabbits. J

Pharm Sci. 1975; 64:1312-1316.

Paul W,and Sharma C. Chitosan, a drug carrier for the 21st century, STP. Pharma

Sci. 2000; 10:5-22.

Perrottet N, Beguin A, Meylan P, Pascual M, Manuel O, Buclin T. Determination

of aciclovir and ganciclovir in human plasma by liquid chromatography-

spectrofluorimetric detection and stability studies in blood samples. J Chromat B:

Anal Techn Biomed Lif Sci. 2007; 852:420-429.

Pflugfelder, SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;

137: 337–342.

Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit

RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J

Pharm Sci 2002; 16:53-61.

Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded

acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;

23:3247-3255.

Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G. Preparation

and characterization of eudragit retard nanosuspensions for the ocular delivery of

cloricromene. AAPS PharmSciTech. 2006; 7:E27.

Ponchel G, Touchard F, Duchfine D, Peppas NA. Bioadhesive analysis of

controlled-release systems. I. Fracture and interpenetration analysis in poly (acrylic

acid)-containing systems. J Control Release 1987; 5:129-141.

DES References


Chapter 9

Qu X, Khutoryanskiy VV, Stewart A, Rahman S, Papahadjopoulos-Sternberg B,

Dufes C, McCarthy D, Wilson CG, Lyons R, Carter KC, Schätzlein A, Uchegbu IF.

al. Carbohydrate-based micelle clusters which enhance hydrophobic drug

bioavailability by up to 1 order of magnitude. Biomacromolecules 2006; 7:3452–

3459.

Quintana A, Raczka E, Piehler L, Lee I, Myc A, Majoros I, Patri AK, Thomas T,

Mulé J, Baker JR Jr. Design and function of a dendrimer-based therapeutic

nanodevice targeted to tumor cells through the folate receptor. Pharm Res. 2002;

19:1310–1316.

Raja Naresh RA, Handrashekhar G, Pillai GK, Udupa N. (1994). Antiinflammatory

activity of niosome encapsulated diclofenac sodium with Tween-85 in Arthitic rats.

Ind J Pharmacol. 1994; 26:46–48.

Rao SN. Reversibility of dry eye deceleration after topical cyclosporine 0.05%

withdrawal. J Ocul Pharmacol Ther. 2011; 27: 603-609.

Rashed MS, Bucknall MP, Little D, Awad A, Jacob M, Alamoudi M, et al.

Screening blood spots for inborn errors of metabolism by electrospray tandem mass

spectrometry with a microplate batch process and a computer algorithm for

automated of abnormal profiles. Clin Chem 1997; 43:1129-1141.

Robinson J.R, Mlynek GM. 1995. Bioadhesive and phase-change polymers for

ocular drug delivery. Adv Drug Deliv Rev. 1995; 16: 45-50.

Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery.

Drug Discov Today. 2008; 13:144–151.

Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging.

Drug Discov Today 2003; 8:1112–1120.

Sakai T, Kohno H, Ishihara T, Higaki M, Saito S, Matsushima M, Mizushima Y,

Kitahara K. Treatment of experimental autoimmune uveoretinitis with poly(lactic

acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res. 2006;

82:657-663.

Salgueiro A, Egea MA, Espina M, Valls O, García ML. Stability and ocular

tolerance of cyclophosphamide-loaded nanospheres. J Microencapsul. 2004;

21:213-223.

Schaeffer HE, Krohn DL. Liposomes in topical drug delivery. Invest Ophthalmol

Vis Sci. 1982; 22:220–227.

DES References


Chapter 9

Schipper NG, Olsson S, Hoogstraate JA, deBoer AG, Vårum KM, Artursson P

Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of

absorption enhancement. Pharm Res 1997; 14:923-929.

Schipper, NGM, Olsson S, Hoostraate JA, Deboer AG, Varum KM, and Artursson

P. Chitosan as absorption for poorly absorbable drug 2: mechanism of absorption

enhancement. Pharm Res. 1997; 14:923-929.

Schmalfuss U, Neubert R, Wohlrab W. Modification of drug penetration into

human skin using microemulsions. J. Control Release. 1997; 46:279-285.

Schoenwald RD, Stewart P. Effect of particle size on ophthalmic bioavailability of

dexamethasone suspensions in rabbits. J. Pharm Sci. 1980; 69:391-394.

Schoenwald RD, Ward R. Relationship between steroid permeability across excised

rabbit cornea and octanol-water partition coefficients. J Pharm Sci 1978; 67:786-

788.

Schutz E, Svinarov D, Shipkova M, Niedman PD, Armstrong VW, Wieland E, et al.

Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical

overview of performance characteristics and comparison with HPLC. Clin Chem

1998; 44:2158-2164.

Seyfoddin A, Shaw J, Al-Kassas R. Solid lipid nanoparticles for ocular drug

delivery. Drug Deliv. 2010; 17:467-489.

Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and

bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm

Biopharm, 2007; 66:227.

Shaunak S, Thomas S, Gianasi E, Godwin A, Jones E, Teo I, Mireskandari K,

Luthert P, Duncan R, Patterson S, Khaw P, Brocchini S. Polyvalent dendrimer

glucosamine conjugates prevent scar tissue formation. Nat Biotechnol 2004;

22:977–984.

Shedden AH, Laurence J, Barrish A, Olah TV. Plasma timolol concentrations of

timolol maleate: timolol gel-forming solution (TIMOPTICXE) once daily versus

timolol maleate ophthalmic solution twice daily. Doc. Ophthalmol. 2001; 103:73-

79.

Sheikpranbabu S, Kalishwaralal K, Venkataraman D, Eom SH, Park J, Gurunathan

S. Silver nanoparticles inhibit vegf-and il-1 -induced vascular Permeability via src

dependent pathway in porcine retinal Endothelial cells J Nanobiotechnology. 2009

30; 7:8.

DES References


Chapter 9

Shen Y, Tu J. Preparation and ocular pharmacokinetics of ganciclovir liposomes.

Aaps J 2007; 9:E371–377.

Shimazaki H, Hironaka K, Fujisawa T, Tsuruma K, Tozuka Y, Shimazawa M,

Takeuchi H, Hara H. Edaravone-loaded liposome eyedrops protect against light-

induced retinal damage in mice. Invest Ophthalmol Vis Sci. 2011; 52:7289-7297.

Sieg JW, Robinson JR. Vehicle effects on ocular drug bioavailability II: Evaluation

of pilocarpine. J. Pharm Sci. 1997; 66:1222-1228.

Sintzel MB, Bernatchez SF, Tabatabay C, Gurny R. Biomaterials in ophthalmic

drug delivery. Eur J Pharm Biopharm 1996; 42:358-374.

Slovin EM, Robinson JR. Bioadhesives in ocular drug delivery. In: Edman P,

editor, Biopharmaceutics of ocular drug delivery. CRC Press, Boca Raton, Florida;

1993. p. 145-57.

Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. Enteral absorption of

insulin in rats from mucoadhesive chitosan coated liposomes. Pharm Res 1996;

13:896-901.

Taniguchi K, Yamamoto Y, Itakura K, Miichi H, Hayashi S. Assessment of ocular

irritability of liposome preparations. J Pharmacobiodyn. 1988; 9:607-611.

Tenjarla, S. Microemulsions: an overview and pharmaceutical applications. Crit

Rev. Ther. Drug Carrier Syst.1999; 16:461.

Teshima D, Otsubo K, Yoshida T, Itoh Y, Oishi R. A simple and simultaneous

determination of acyclovir and ganciclovir in human plasma by high-performance

liquid chromatography. Biomed Chromat.2003; 17:500-503.

Tian B, Luo Q, Song S, Liu D, Pan H, Zhang W, He L, Ma S, Yang X, Pan W.

Novel surface-modified nanostructured lipid carriers with partially deacetylated

Tiffany JM. The viscosity of human tears. Int Ophthalmol. 1991; 15:371-376.

Tsuchie M, Hara S, Kimura M, Fujii M, Ono N, Kai M. Determination of anti-virus

drug, ganciclovir, in human serum by HPLC with precolumn fluorescence

derivatization using phenylglyoxal. Anal Sci. 2001; 17:811-814.

Uchegbu IF, Duncan R. Niosomes containing N-(2- hydroxypropyl)methacrylamide

copolymer- doxorubicin (PK1):Effect of method of preparation and choice of

surfactant on noisome characteristics and a preliminary study of body distribution.

Int J Pharm. 1997; 155:7–17.

DES References


Chapter 9

Uchegbu IF, Florence AT. Non-ionic surfactant vesicles (niosomes): Physical and

pharmaceutical chemistry. Adv Coll Interf Sci. 1995; 58:1–55.

Uchegbu IF, Sadiq L, Arastoo M, Gray AI, Wang W, Waigh RD, Schätzlein AG.

Quaternary ammonium palmitoyl glycol chitosan—a new polysoap for drug

delivery. Int J Pharm. 2001; 224:185–199.

Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug

delivery. Int J Pharm. 1998; 172:33–70.

Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of

cyclosporin A. Ocul Immunol Inflamm. 2010; 18: 352-361.

Van Ooteghem M. Preparations ophtalmiques. In: Galenica, editor, Technique and

documentation. Lavoisier, Paris; 1995.

Van Ooteghem, M. Factors influencing the retention of ophhtalmic solutions on the

eye surface. In Saettone MF, Bucci M, & Speiser P. editors. Ophthalmic Drug

Delivery. Biopharmaceutical, Technological and Clinical Aspects, Padova: Livinia

Press. 1987. Vol. 11, pp. 7-17.

Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles

for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release. 2005;

102:23-38.

Vandamme TF, Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles

for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005;

102:23–38.

Vandamme TF. Microemulsions as ocular drug delivery systems: recent

developments and future challenges. Prog Retin Eye Res. 2002; 21:15–34.

Vandervoort J, Ludwig A. Ocular drug delivery: nanomedicine applications

Nanomedicine (Lond). 2007; 2:11-21.

Vandervoort J, Ludwig A. Preparation and evaluation of drug-loaded gelatin

nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm. 2004; 57:251-261.

VanSantvliet L, and Ludwig A. The influence of penetration enhancers on the

volume instilled of eye drops. Eur J Pharm Biopharm. 1998; 45:189-198.

Vega E, Gamisans F, García ML, Chauvet A, Lacoulonche F, Egea MA. PLGA

nanospheres for the ocular delivery of flurbiprofen: drug release and interactions. J

Pharm Sci. 2008; 97:5306-5317.

Vyas SP, Mysore N, Jaitely V, Venkatesan N. Discoidal niosome based controlled

ocular delivery of timolol maleate. Pharmazie. 1998; 53:466-469.

DES References


Chapter 9

Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Hyaluronic acid modified chitosan

nanoparticles for effective management of glaucoma: development,

characterization, and evaluation. J Drug Target. 2010; 18:292-302.

Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Nanocarriers in ocular drug delivery:

an update review. Curr Pharm Des. 2009; 15:2724-2750.

Wang JJ, Zeng ZW, Xiao RZ, Xie T, Zhou GL, Zhan XR, Wang SL. Recent

advances of chitosan nanoparticles as drug carriers. Int J Nanomed 2011; 6: 765-

774.

Wang S, Zhang J, Jiang T, Zheng L, Wang Z, Zhang J, Yu P. Protective effect of

Coenzyme Q(10) against oxidative damage in human lens epithelial cells by novel

ocular drug carriers. Int J Pharm. 2011; 403:219-229.

Wei G, Xu H, Ding PT, Li SM, Zheng JM. Thermosetting gels with modulated

gelation temperature for ophthalmic use: the rheological and gamma scintigraphic

studies. Control Release. 2002; 83:65-74.

Wood RW, Li VHK, Kreuter J, Robinson JR. Ocular disposition of poly-hexyl-2-

cyano (3-14C) acrylate nanoparticles in the albino rabbit. Int J Pharm 1985; 23:175-

183.

Xu HR, Li XN, Chen WL, Liu GY, Chu NN, Yu C. A sensitive assay for

simultaneous determination of plasma concentrations of valganciclovir and its

active metabolite ganciclovir by LC/MS/MS. J Chromat B: Anal Techn Biomed Lif

Sci. 2007; 848:329- 334.

Xu Y, and Du Y. Effect of molecular structure of chitosan on protein delivery

properties of chitosan nanoparticles. Int J Pharm. 2003; 250:215-226.

Yamaguchi M, Ueda K, Isowaki A, Ohtori A, Takeeuchi H, Ohguro N, Tojo K.

Mucoadhesives Properties of chitosan coated phthalmic lipid emulsion containing

indomethacin in tear fluid. Biol Pharm Bull. 2009; 32:1266-1271

Yuan JS, Ansari M, Samaan M, Acosta EJ. Linker-based lecithin microemulsions

for transdermal delivery of lidocaine. Int J Pharm. 2008; 349:130.

Yuan XB, Yuan YB, Jiang W, Liu J, Tian EJ, Shun HM, Huang DH, Yuan XY, Li

H, Sheng J. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for

immunosuppression in corneal transplantation, Int J Pharm 2008; 349:241–248.

Zeisig R, Shimada K, Hirota S, Arndt D. Effect of sterical stabilization on

macrophage uptake in vitro and on thickness of the fixed aqueous layer of

DES References


Chapter 9

liposomes made from alkylphosphocholines. Biochim Biophys Acta.1996;

1285:237–245.

Zhang L, Li Y, Zhang C, Wang Y, Song C. Pharmacokinetics and tolerance study

of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits. Int J

Nanomedicine. 2009; 4:175-183.

Zhang R, He R, Qian J, Guo J, Xue K, Yuan YF. Treatment of experimental

autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506)

encapsulated in liposomes. Invest Ophthalmol Vis Sci. 2010; 51:3575-3582.

Zignani M, Tabatabay C, Gurny R. Topical semi-solid drug delivery: kinetics and

tolerance of ophthalmic hydrogels. Adv Drug Deliv Rev. 1995; 16: 51-60.

Zimmer A, Kreuter J, Robinson JR.. Studies on the transport pathway of PBCA

nanoparticles in ocular tissues. J Microencaps.1991; 8:497–504.

Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery

systems. Adv Drug Deliv. Rev. 1995; 16:61-73.

Zimmer A, Mutschler E, Lambrecht G, Mayer D, Kreuter J. Pharmacokinetic and

Pharmacodynamic aspects of an ophthalmic pilocarpine nanoparticle-delivery-

system. Pharm Res. 1994; 11:1435-1442.

Zimmer AK, Maincent P, Thouvenot P, Kreuter J. Hydrocortisone delivery to

healthy and inflamed eyes using a micellar polysorbate 80 solution or albumin

nanoparticles. Int J Pharm. 1994; 110:211-222.

Zimmera AK, Zerbeb H, Kreuter J. Evaluation of pilocarpine-loaded albumin

particles as drug delivery systems for controlled delivery in the eye I. In vitro and in

vivo characterisation. J Control Release. 1994; 32:57-70.

des chapter 9 references - information and library...

Documents